Experience With Rapid Drug Desensitisation WithChemotherapeutics; A Single-Centre Retrospective Study

Abstract

Objectives: Our aim is to share our platinum salt-, taxane- and irinotecan-induced rapid drug desensitisation (RDD)experiences. Methods: In our study, the demographic data, initial HSR grades, skin test results and RDD success rates of patientswho underwent a 12-step RDD protocol, and their breakthrough reactions (BTR) observed during desensitisation wereretrospectively examined. Results: The mean age of 28 patients who underwent RDD (platinum=22, taxane=4, irinotecan=2) was 57 (40-72), and53.6% of the patients were female. 87 RDD procedures (platinum=56, taxane=21, irinotecan=10) were performed intotal. 32.1% of the initial HSRs were grade 3 and 60.7% were grade 2. In terms of skin test results, 17 patients in the plati num group showed positivity to skin test. Two patients with negative results had a positive result on graded challenge.One patient in the taxane group had a negative skin test result yet had a grade 3 HSR. BTRs were observed in 46.4% ofour patients – but none were at grade 3 in severity. 5 patients were unable to successfully complete the RDD protocol. Conclusion: 12-step protocol was proven safe and efficient in our experiences with RDD. Our RDD success rate was 94.3%.